Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Int J Gynecol Pathol. 2022 May 20;42(2):182–191. doi: 10.1097/PGP.0000000000000868

Figure 3.

Figure 3.

Molecular study of case 1. Sanger sequencing showed that the KRAS G12V mutation was present in both the serous borderline tumor/non-invasive low-grade serous carcinoma (SBT/niLGSC) and the mesonephric-like adenocarcinoma (MLA), indicating their clonal origin. Star (*) indicates mutational site.